Curated News Stories

BioVaxys Phase 2 Data Shows Maveropepimut Combination Effective in Metastatic Bladder Cancer

BioVaxys Phase 2 Data Shows Maveropepimut Combination Effective in Metastatic Bladder Cancer

BioVaxys Technology Corp. reported positive Phase 2 clinical results demonstrating that its immunotherapy maveropepimut-S combined with pembrolizumab and low-dose cyclophosphamide achieved objective responses in metastatic bladder cancer patients, including those previously resistant to checkpoint inhibitors, potentially expanding treatment options ahead of upcoming patent expirations for major cancer drugs.

Read the full story